AR027528A1 - Preparacion farmaceutica para el tratamiento de rinitis alergica y/o vasomotriz o conjuntivitis alergica, la utilizacion de dicha preparacion para laobtencion de medicamentos y el procedimiento para preparar dichos medicamentos - Google Patents

Preparacion farmaceutica para el tratamiento de rinitis alergica y/o vasomotriz o conjuntivitis alergica, la utilizacion de dicha preparacion para laobtencion de medicamentos y el procedimiento para preparar dichos medicamentos

Info

Publication number
AR027528A1
AR027528A1 ARP010100731A ARP010100731A AR027528A1 AR 027528 A1 AR027528 A1 AR 027528A1 AR P010100731 A ARP010100731 A AR P010100731A AR P010100731 A ARP010100731 A AR P010100731A AR 027528 A1 AR027528 A1 AR 027528A1
Authority
AR
Argentina
Prior art keywords
medicines
allergic
preparation
procedure
treatment
Prior art date
Application number
ARP010100731A
Other languages
English (en)
Original Assignee
Viatris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Gmbh filed Critical Viatris Gmbh
Publication of AR027528A1 publication Critical patent/AR027528A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe una combinacion farmacéutica para la administracion topica u oral de un antihistamínico no sedante a excepcion de los compuestos del tipo de laloratadina en combinacion con un antagonista de leucotrieno, seleccionado de un antagonista del leucotrieno D4 o el inhibidor de la 5-lipoxigenasa o elantagonista de FLAP y, llegado el caso, vehículos, diluyentes y excipientes usuales fisiologicamente inofensivos para la profilaxis y el tratamiento de rinitisalérgica y/o vasomotriz o conjuntiv itis alérgica. También se describe la utilizacion de dicha combinacion farmacéutica para la preparacion de medicamentos y elprocedimiento para preparar tales medicamentos.
ARP010100731A 2000-02-17 2001-02-16 Preparacion farmaceutica para el tratamiento de rinitis alergica y/o vasomotriz o conjuntivitis alergica, la utilizacion de dicha preparacion para laobtencion de medicamentos y el procedimiento para preparar dichos medicamentos AR027528A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10007203A DE10007203A1 (de) 2000-02-17 2000-02-17 Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis

Publications (1)

Publication Number Publication Date
AR027528A1 true AR027528A1 (es) 2003-04-02

Family

ID=7631276

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100731A AR027528A1 (es) 2000-02-17 2001-02-16 Preparacion farmaceutica para el tratamiento de rinitis alergica y/o vasomotriz o conjuntivitis alergica, la utilizacion de dicha preparacion para laobtencion de medicamentos y el procedimiento para preparar dichos medicamentos

Country Status (27)

Country Link
US (1) US6436924B2 (es)
EP (1) EP1265615B1 (es)
JP (1) JP5529362B2 (es)
KR (1) KR100764329B1 (es)
CN (1) CN1241569C (es)
AR (1) AR027528A1 (es)
AT (1) ATE287266T1 (es)
AU (1) AU781177B2 (es)
BR (1) BR0108445A (es)
CZ (1) CZ296395B6 (es)
DE (2) DE10007203A1 (es)
DK (1) DK1265615T3 (es)
ES (1) ES2236189T3 (es)
HK (1) HK1053792A1 (es)
HU (1) HU228927B1 (es)
IL (2) IL151106A0 (es)
MX (1) MXPA02008064A (es)
NO (1) NO328153B1 (es)
NZ (1) NZ520470A (es)
PL (1) PL198357B1 (es)
PT (1) PT1265615E (es)
RU (1) RU2292208C2 (es)
SK (1) SK285990B6 (es)
TW (1) TWI296525B (es)
UA (1) UA72587C2 (es)
WO (1) WO2001060407A2 (es)
ZA (1) ZA200206575B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
FR2833493B1 (fr) * 2001-12-18 2005-09-23 Ioltechnologie Production Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble
WO2003101434A2 (en) * 2001-12-21 2003-12-11 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
WO2004035741A2 (en) * 2002-10-17 2004-04-29 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
WO2004069338A1 (en) * 2003-01-31 2004-08-19 Schering Corporation Use of combinations of h1 and h3 histamine receptor antagonists for the preparation of a medicament for the treatment of allergic skin and allergic ocular conditions
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
US20050272051A1 (en) * 2003-09-17 2005-12-08 Decode Genetics Ehf. Methods of preventing or treating recurrence of myocardial infarction
WO2005030331A1 (en) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
PT1713473E (pt) * 2004-02-06 2013-05-13 Meda Pharma Gmbh & Co Kg Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd
SI1713471T1 (sl) * 2004-02-06 2012-07-31 Meda Pharma Gmbh & Co Kg Kombinacija antiholinergikov in inhibitorjev fosfodiesteraze tipa za zdravljenje respiratornih bolezni
PE20060484A1 (es) * 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
WO2006058022A1 (en) 2004-11-24 2006-06-01 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
MX2007011273A (es) * 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
US7405302B2 (en) * 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
AU2006329042B2 (en) 2005-12-21 2012-02-02 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
WO2007126865A2 (en) * 2006-03-30 2007-11-08 Patrin Pharma Leukotriene antagonists via nasal drug delivery
WO2008067566A1 (en) 2006-11-30 2008-06-05 Amira Pharmaceuticals, Inc. Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
EP2222299B1 (en) * 2007-11-19 2011-11-23 Bausch & Lomb Incorporated Use of levocabastine for modulating generation of pro-inflammatory cytokines
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
WO2010107525A1 (en) * 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
PT2408453T (pt) 2009-03-17 2022-04-05 Nicox Ophthalmics Inc Formulações oftálmicas de cetirizina e métodos de utilização
EP3563842A1 (en) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR101418404B1 (ko) * 2012-01-06 2014-07-10 한미약품 주식회사 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제
WO2014164299A1 (en) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
US9783529B2 (en) 2013-03-13 2017-10-10 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis
KR101555908B1 (ko) * 2013-12-19 2015-09-25 한미약품 주식회사 몬테루카스트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 액상 제제 및 이의 제조방법
US10080748B2 (en) 2014-02-04 2018-09-25 Bioscience Pharma Partners, Llc Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system
EP3193875B1 (en) 2014-09-15 2022-02-16 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
AU2020206036A1 (en) * 2019-01-11 2021-08-05 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors
CN110721189A (zh) * 2019-11-19 2020-01-24 贵州云峰药业有限公司 一种皮肤消毒剂
US11173117B2 (en) * 2020-02-03 2021-11-16 Taro Pharmaceutical Industries Ltd. Topical Montelukast formulations
CN116284470B (zh) * 2023-02-15 2024-08-02 广西中医药大学 一种海蛇尾多糖硫酸酯衍生物的制备方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
DE3877904D1 (de) 1987-11-13 1993-03-11 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
JPH0655673B2 (ja) 1988-04-27 1994-07-27 シェリング・コーポレーション Ｐａｆ拮抗薬‐抗ヒスタミン剤の組合せ及び使用方法
ATE363283T1 (de) * 1992-08-03 2007-06-15 Sepracor Inc Terfenadin-carboxylat und die behandlung von hautreizung
EP1014972A4 (en) * 1996-02-08 2004-12-08 Merck & Co Inc TREATMENT METHOD AND PHARMACEUTICAL COMPOSITION
DE19610882A1 (de) * 1996-03-20 1997-09-25 Dresden Arzneimittel Neue 1,3,5-trisubstituierte Indazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
CN1253508A (zh) * 1997-04-30 2000-05-17 沃尼尔－朗伯公司 局部鼻用抗炎组合物
US6242179B1 (en) 1997-12-17 2001-06-05 Incyte Pharmaceuticals, Inc. Human phosphatases
ATE331522T1 (de) * 1997-12-23 2006-07-15 Schering Corp Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum
US6194431B1 (en) * 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors

Also Published As

Publication number Publication date
ES2236189T3 (es) 2005-07-16
DE50105126D1 (de) 2005-02-24
KR20020083161A (ko) 2002-11-01
RU2292208C2 (ru) 2007-01-27
AU781177B2 (en) 2005-05-12
DK1265615T3 (da) 2005-05-30
IL151106A0 (en) 2003-04-10
CN1400903A (zh) 2003-03-05
CZ20022700A3 (cs) 2002-11-13
DE10007203A1 (de) 2001-08-23
HK1053792A1 (en) 2003-11-07
US20010025040A1 (en) 2001-09-27
HUP0204079A3 (en) 2006-07-28
EP1265615A2 (de) 2002-12-18
PT1265615E (pt) 2005-05-31
SK285990B6 (sk) 2008-01-07
AU4058401A (en) 2001-08-27
JP5529362B2 (ja) 2014-06-25
CN1241569C (zh) 2006-02-15
NO20023818L (no) 2002-08-12
HU228927B1 (en) 2013-06-28
ZA200206575B (en) 2003-05-14
NO328153B1 (no) 2009-12-21
US6436924B2 (en) 2002-08-20
ATE287266T1 (de) 2005-02-15
PL355818A1 (en) 2004-05-17
SK11752002A3 (sk) 2002-11-06
UA72587C2 (uk) 2005-03-15
BR0108445A (pt) 2003-04-01
EP1265615B1 (de) 2005-01-19
NO20023818D0 (no) 2002-08-12
CZ296395B6 (cs) 2006-03-15
KR100764329B1 (ko) 2007-10-05
TWI296525B (en) 2008-05-11
WO2001060407A2 (de) 2001-08-23
NZ520470A (en) 2004-05-28
JP2003522803A (ja) 2003-07-29
MXPA02008064A (es) 2004-04-05
PL198357B1 (pl) 2008-06-30
IL151106A (en) 2008-06-05
HUP0204079A2 (hu) 2003-04-28
WO2001060407A3 (de) 2002-03-07
RU2002123345A (ru) 2004-03-20

Similar Documents

Publication Publication Date Title
AR027528A1 (es) Preparacion farmaceutica para el tratamiento de rinitis alergica y/o vasomotriz o conjuntivitis alergica, la utilizacion de dicha preparacion para laobtencion de medicamentos y el procedimiento para preparar dichos medicamentos
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
CU20000176A7 (es) Composiciones de celecoxib
BR9916224A (pt) Forma de dosagem farmacêutica oral, processos para a manufatura de uma forma de dosagem fixa, para o tratamento e a profilaxia de distúrbios gastrintestinais e para evitar efeitos colaterias gastrintestinais, uso de uma forma de dosagem, combinação, e, embalagem tipo ampola
CL2011000710A1 (es) Combinacion farmaceutica que comprende un inhibidor especifico de smoothened y un inhibidor de cinasa pi3 especifico; y uso en el tratamiento de cancer.
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
AR034320A1 (es) Forma de dosificacion farmaceutica del mesilato de nelfinavir amorfo
UY26926A1 (es) Derivados de la quinolina y quinazolina
ES2390226T3 (es) Tratamiento de enfermedades infecciosas
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
BR0206695A (pt) Formas de dosagem de epotilonas para administração oral
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
AR008293A1 (es) Composicion que comprende una cantidad antihistaminica para el tratamiento de las respuestas alergicas de las vias respiratorias superiores
AR011134A1 (es) Derivados de imidazo piridina substituidos para la inhibicion de la secrecion de acido gastrico; una sal del mismo, procedimiento para su preparacion, formulacion farmaceutica que los contiene y el uso de dicho compuesto para la manufactura de un medicamento
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
AR032778A1 (es) Benzimidazoles sustituidos, y su utilizacion para la preparacion de medicamento
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
UY26720A1 (es) Derivados del pirrol
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
DK0527081T3 (da) Hidtil ukendte substituerede 3-piperazinylalkyl-2,3-dihydro-1,3-4H-benzoxazin-4-oner, deres fremstilling og terapeutiske anvendelse
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
SE9900070D0 (sv) New use
ES2089974B1 (es) Utilizacion de los derivados de 1-(4-)4-aril (o heteroaril)-1-piperazinil)-butil)-1-h-azol para la preparacion de medicamentos destinados al tratamiento de los trastornos de la secrecion gastrica.
CO5251412A1 (es) Composicion farmaceutica de mirtazapina para administracion peroral con cubierta polimerica
CO5640069A2 (es) Forma de dosificacion oral de mesilato de saquinavir

Legal Events

Date Code Title Description
FC Refusal